Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2023-04-18 00:00:00 ET · period of report 2023-04-14 · accession 0000899243-23-011381 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-18 | 2023-04-14 | NTLA | CHASE WILLIAM J | Dir | A - Grant | $0.00 | +10.5K | 17.3K | +154% | $0 |
| D | 2023-04-18 | 2023-04-14 | NTLA | CHASE WILLIAM J | Dir | A - Grant | $0.00 | +14.9K | 14.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-14 | A | A | 10,483 | $0.00 | 17,283 | D | — | — | (F1) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-04-14 | A | A | 14,931 | $0.00 | 14,931 | D | $38.16 · — to 2033-04-13 | 14,931 Common Stock | (F2) This option was granted on April 14, 2023 with respect to 14,931 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on April 14, 2024 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter. |